FDA perspective on anti-TNF treatments.

@article{Schwieterman1999FDAPO,
  title={FDA perspective on anti-TNF treatments.},
  author={William D Schwieterman},
  journal={Annals of the rheumatic diseases},
  year={1999},
  volume={58 Suppl 1},
  pages={
          I90-1
        }
}
Although there are many points I would like to make about the FDA's perspective on anti-TNF treatments, I have limited myself to those 10 that I believe are most important. I present several of these less as absolutes than as stimulants for discussion, as I wish to make use of the expertise at this conference for furthering our collective understanding of how anti-TNF agents might best be used. There are no long term data on the safety of anti-TNF agents. Controlled safety data exist, to date… CONTINUE READING

Topics from this paper.